NCT00004985

Brief Summary

The purpose of this study is to look at the effectiveness of an anti-HIV drug combination that adds capravirine in patients who have failed their first drug combination treatment.

Trial Health

85
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
75

participants targeted

Target at P25-P50 for phase_2 hiv-infections

Geographic Reach
2 countries

34 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2000

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

March 15, 2000

Completed
1.5 years until next milestone

First Posted

Study publicly available on registry

August 31, 2001

Completed
Last Updated

June 24, 2005

Status Verified

March 1, 2001

First QC Date

March 15, 2000

Last Update Submit

June 23, 2005

Conditions

Keywords

HIV-1Drug Therapy, CombinationHIV Protease InhibitorsRNA, ViralReverse Transcriptase InhibitorsAnti-HIV AgentsViral LoadNelfinavir

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients may be eligible for this trial if they:
  • Are HIV-positive.
  • Have a CD4 cell count more than 50/mm3.
  • Are at least 18 years old.
  • Have adequate blood, kidney, and liver functions.
  • Are currently taking an anti-HIV drug combination of an NNRTI plus 1 or more NRTIs for more than 28 days and are failing that combination.

You may not qualify if:

  • Patients will not be eligible for this trial if they:
  • Have had any protease inhibitor or capravirine treatment.
  • Have been given any drug that interferes with their immune system or with the study drugs within 28 days of study entry.
  • Have had radiation therapy within 28 days of study entry.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (34)

Phoenix Body Positive

Phoenix, Arizona, 85016, United States

Location

Pacific Oaks Med Group

Beverly Hills, California, 90211, United States

Location

First Choice Medical

Palm Springs, California, 92262, United States

Location

Apogee Med Group

San Diego, California, 92101, United States

Location

Saint Francis Mem Hosp / HIV Care Unit

San Francisco, California, 94109, United States

Location

Kaiser Foundation Hospital

San Francisco, California, 94118, United States

Location

Harbor - UCLA Med Ctr

Torrance, California, 90502, United States

Location

Univ of Colorado Health Sciences Ctr

Denver, Colorado, 80262, United States

Location

Bach and Godofsky

Bradenton, Florida, 34205, United States

Location

Clin Research of West Florida

Clearwater, Florida, 33765, United States

Location

Community Health Care

Fort Lauderdale, Florida, 33306, United States

Location

Therafirst Med Ctr

Fort Lauderdale, Florida, 33308, United States

Location

South Shore Hosp

Miami, Florida, 33139, United States

Location

Immunity Care and Research Inc

Miami Beach, Florida, 33139, United States

Location

Orange County Health Dept

Orlando, Florida, 32805, United States

Location

Infectious Diseases Associates

Sarasota, Florida, 34239, United States

Location

Hillsborough County Health Dept

Tampa, Florida, 33602, United States

Location

Treasure Coast Infectious Disease Consultants

Vero Beach, Florida, 32960, United States

Location

Polk County Health Dept

Winter Haven, Florida, 33881, United States

Location

AIDS Research Consortium of Atlanta

Atlanta, Georgia, 30308, United States

Location

Braude Mermin Spivey MD PC

Atlanta, Georgia, 30309, United States

Location

Massachusetts Gen Hosp

Boston, Massachusetts, 02114, United States

Location

Fenway Community Health Ctr

Boston, Massachusetts, 02115, United States

Location

VAMC New Jersey Healthcare System

East Orange, New Jersey, 07018, United States

Location

Jersey Shore Med Ctr

Neptune City, New Jersey, 07753, United States

Location

Infectious Disease Assoc of Central Jersey

Somerville, New Jersey, 08876, United States

Location

Biomedical Research Alliance of New York

Jamaica, New York, 11432, United States

Location

North Shore Univ Hosp

Manhasset, New York, 11030, United States

Location

Liberty Medical

New York, New York, 10014, United States

Location

Mount Sinai Med Ctr

New York, New York, 10029, United States

Location

Central Texas Clinical Research

Austin, Texas, 78705, United States

Location

Univ TX Galveston Med Branch

Galveston, Texas, 77555, United States

Location

Infectious Disease Physicians Inc

Annandale, Virginia, 22203, United States

Location

Clinical Research Puerto Rico Inc

San Juan, 009091711, Puerto Rico

Location

MeSH Terms

Conditions

HIV Infections

Interventions

capravirineNelfinavir

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System Diseases

Intervention Hierarchy (Ancestors)

IsoquinolinesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Design

Study Type
interventional
Phase
phase 2
Purpose
TREATMENT
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

March 15, 2000

First Posted

August 31, 2001

Study Start

January 1, 2000

Last Updated

June 24, 2005

Record last verified: 2001-03

Locations